Anebulo Pharmaceuticals, Inc.
ANEB
$2.30
-$0.01-0.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.45% | 17.73% | 26.92% | 31.72% | 30.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 152.65% | 363.72% | 650.94% | -- | -- |
| Total Other Non-Cash Items | 90.64% | 59.41% | 34.50% | -5.50% | -14.22% |
| Change in Net Operating Assets | 138.31% | -76.07% | -16,670.83% | -152.21% | -168.64% |
| Cash from Operations | 21.52% | 24.04% | 30.63% | 32.02% | 16.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -87.02% | 10.64% | 100.00% | 80.32% | 80.32% |
| Cash from Financing | 23,951.44% | 11,496.09% | 11,585.45% | 80.32% | -100.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 204.67% | 190.19% | 186.03% | 33.45% | -146.99% |